SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Bumble, Inc. – BMBL
NEW YORK, Oct. 17, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Bumble, Inc. (“Bumble” or the “Company”) (NASDAQ: BMBL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Bumble, Inc. – BMBL
NEW YORK, Oct. 17, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Bumble, Inc. (“Bumble” or the “Company”) (NASDAQ: BMBL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Bumble, Inc. – BMBL
NEW YORK, Oct. 17, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Bumble, Inc. (“Bumble” or the “Company”) (NASDAQ: BMBL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. – MGX
NEW YORK, Oct. 17, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-58
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. – MGX
NEW YORK, Oct. 17, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-58
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. – MGX
NEW YORK, Oct. 17, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-58
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc. – MGX
NEW YORK, Oct. 17, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-58
AusperBio to Present Ongoing AHB-137 Clinical Data in Late-Breaking Oral Presentation at AASLD 2024
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ — AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced that new clinical data from its lead candidate AHB-137, an antisense oligonucleotide (ASO) therapeutic, will be f
AusperBio to Present Ongoing AHB-137 Clinical Data in Late-Breaking Oral Presentation at AASLD 2024
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ — AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced that new clinical data from its lead candidate AHB-137, an antisense oligonucleotide (ASO) therapeutic, will be f
AusperBio to Present Ongoing AHB-137 Clinical Data in Late-Breaking Oral Presentation at AASLD 2024
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ — AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced that new clinical data from its lead candidate AHB-137, an antisense oligonucleotide (ASO) therapeutic, will be f
